Vivet Therapeutics announces different presentations on its lead product, VTX-801, at the upcoming 2018 Copper Meeting in Sorrento (Italy) on September 23-28, 2018. Dr. Gloria Gonzalez-Aseguinolaza, Vivet CSO & Head of the Gene Therapy Dept. at the Fundación para la Investigación Médica Aplicada (FIMA) and Dr. Bernard Benichou, Vivet CMO, will present new preclinical data on VTX-801, generated by Vivet and FIMA in the context of their strategic research collaboration. VTX-801 is an adeno-associated virus (AAV) gene therapy treatment containing Vivet’s proprietary mini-ATP7B copper transporter which targets the liver to restore copper homeostasis in Wilson’s Disease patients. The oral presentation, entitled “Hepatic expression of a miniATP7B gene results in restoration of copper homeostasis in a clinically relevant Wilson’s disease model”, will take place on Monday September 24, 2018 at 11:30 am (Session 3: Copper and metabolism) and Vivet will be also present a poster entitled “Preclinical validation of copper 64 as a translational tool for evaluating the pharmacodynamics of VTX-801 gene therapy in Wilson’s Disease”.